SCYX - SCYX Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Scynexis Inc. (SCYX) Class Action | Benzinga

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Scynexis, Inc. (NASDAQ:SCYX) securities between March 31, 2023 and September 22, 2023. Scynexis is a biotechnology company that is primarily engaged in the development of ibrexafungerp, a broad-spectrum, intravenous (IV)/oral agent for fungal indications.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is this Case About: Scynexis, Inc. (SCYX) Misled Investors Regarding its Quality Control Measures

According to the complaint, the Company has received approval from the United States Food and Drug Administration ("FDA") for the use of ibrexafungerp tablets, distributed under the brand name BREXAFEMME® for the treatment of vulvovaginal candidiasis and the reduction in the incidence of recurrent vulvovaginal candidiasis. The Company is also engaged in clinical investigation of ibrexafungerp for the treatment of invasive fungal infections in hospitalized patients and additional pre-clinical and discovery phase investigations.

The complaint alleges that during the class period, defendants failed to disclose: (1) that the equipment used to manufacture ibrexafungerp was also used to manufacture a non-antibacterial beta-lactam drug ...

SCYX) Class Action>Full story available on Benzinga.com